Mirabegron relaxes arteries from human visceral adipose tissue through antagonism of α
Adipose tissue
Adrenergic receptors
Aging
Mirabegron
Obesity
Journal
Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
03
05
2022
revised:
13
07
2022
accepted:
02
08
2022
pubmed:
8
8
2022
medline:
14
10
2022
entrez:
7
8
2022
Statut:
ppublish
Résumé
As inadequate perfusion has emerged as a key determinant of adipose tissue dysfunction in obesity, interest has grown regarding possible pharmacological interventions to prevent this process. Mirabegron has proved to improve insulin sensitivity and glucose homeostasis in obese humans via stimulation of β Small arteries (116-734 μm) isolated from visceral adipose tissue were studied ex vivo in a wire myograph. After vessels had been contracted, changes in vascular tone in response to mirabegron were determined under different conditions. Mirabegron did not elicit vasorelaxation in vessels contracted with U46619 or high-K Mirabegron induces endothelium-independent vasorelaxation in arteries from visceral adipose tissue, likely through antagonism of α
Identifiants
pubmed: 35934296
pii: S1537-1891(22)00143-4
doi: 10.1016/j.vph.2022.107094
pii:
doi:
Substances chimiques
Acetanilides
0
Adrenergic Agonists
0
Receptors, Adrenergic, alpha-1
0
Thiazoles
0
Phenylephrine
1WS297W6MV
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
76898-47-0
Glucose
IY9XDZ35W2
mirabegron
MVR3JL3B2V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
107094Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.